Clinical Trial Provides Hope for Multiple Myeloma Patients
Findings from two large, international clinical trials show unparalleled survival for patients with multiple myeloma, a blood cancer of the blood-making cells of the bone marrow.
The findings demonstrate that with Revlimid, an oral cancer drug, all measures of myeloma showed significant improvement in patients where previous treatments had failed.
Rush University Medical Center took part in the U.S. study, where a total of 353 patients were studied. According to the study results, patients who received Revlimid had a median survival of 29.6 months, compared to 20.2 months for the placebo group. In the Revlimid group, 61 percent of patients responded to therapy as compared with 19.9 percent in the placebo group.
Multiple myeloma is a cancer of the bone with increasing incidence among younger patients in the recent years. Up to this day, there is no known cure for multiple myeloma.
(Source)
Pingback from Myeloma » Blog Archive » Researchers Transfer Immune Response To Myeloma Patient, Study …
Time March 5, 2008 at 12:13 pm
[...] Clinical Trial Provides Hope for Multiple Myeloma PatientsFindings from two large, international clinical trials show “unprecedented” survival for patients with multiple myeloma, a blood cancer that occurs in the blood-making cells of the bone marrow. The findings demonstrate that with … [...]